Simon Hill Reveals His Full Plaque Protocol and Why He Started a PCSK9 Inhibitor
Simon Hill breaks down his lipid-lowering strategy after three AI platforms gave wildly different readings from the same heart scans.
Summary
Simon Hill shares the complete cardiovascular protocol behind his widely discussed coronary plaque scans. Three AI platforms analyzed the same images and returned results ranging from a 48% reduction to a 20% increase — a sixfold spread in absolute plaque volume. Hill explains why he anchors to one analysis over the others, informed by cardiologist Dr. Matthew Budoff's guidance on AI overestimation concerns. He walks through his nutrition, training, and sleep habits, the supplements he deliberately skipped, and why cumulative ApoB exposure — not a single cholesterol snapshot — is the metric that drives his decisions. Despite encouraging scan results, Hill ultimately chose to start a PCSK9 inhibitor rather than a statin, citing long-term ApoB burden as his primary rationale. He urges listeners to view short-interval scan results, including his own, with healthy skepticism.
Detailed Summary
Coronary artery disease remains the leading cause of death worldwide, and the emerging ability to quantify soft plaque via CT-based imaging has made personal cardiovascular risk assessment more accessible than ever. But as this episode illustrates, the technology is far from standardized — and the gap between platforms can be wide enough to reverse a headline entirely.
Simon Hill, nutrition scientist and host of The Proof, published his own coronary CT scans several weeks before this episode. A 48% reduction in plaque volume over 16.5 months generated significant attention online. In this follow-up, Hill reveals the full picture: the same two scans were analyzed by three separate platforms — HeartFlow, Cleerly, and QAngio — which returned absolute plaque volumes of 11.5, 74, and 60 cubic millimeters respectively. That is a sixfold spread from identical images, reflecting differences in AI methodology, reference databases, and segmentation algorithms.
Hill draws on published concerns about AI overestimation and on input from Dr. Matthew Budoff, a leading expert in cardiac CT, to explain which result he trusts and why. All three platforms agreed that his overall plaque burden is low and not rapidly progressing — a point Hill argues is more meaningful than any single percentage change.
The core of the episode is Hill's cardiovascular protocol. He emphasizes cumulative lifetime ApoB exposure as the primary driver of atherosclerosis risk, arguing that a favorable cholesterol reading today does not erase decades of prior burden. His approach integrates a whole-food, predominantly plant-based diet, structured aerobic and resistance training, optimized sleep, and deliberate avoidance of certain supplements. Despite encouraging scan findings, he started a PCSK9 inhibitor — chosen over a statin — to drive ApoB lower over the long term.
Clinically, this episode is a valuable case study in the limitations of short-interval serial plaque imaging and the importance of anchoring cardiovascular decisions to validated biomarkers like ApoB rather than to AI-generated percentage changes alone.
Key Findings
- Three AI platforms measured the same heart scans and returned plaque volumes of 11.5, 60, and 74 mm³ — a sixfold absolute spread.
- All three analyses agreed on the clinically important point: plaque burden was low and not rapidly progressing.
- Cumulative lifetime ApoB exposure, not a single cholesterol reading, is the key driver of atherosclerosis risk.
- Hill chose a PCSK9 inhibitor over a statin to reduce ApoB further despite already favorable scan results.
- Short-interval coronary scan results should be interpreted with skepticism due to AI methodology and reference database variability.
Methodology
This is a podcast episode presenting a personal case study in which one individual's serial coronary CT scans were analyzed by three commercial AI platforms. Clinical context and interpretation were informed by cardiologist Dr. Matthew Budoff. No controlled study design or comparative cohort was involved.
Study Limitations
This episode is based on a single individual's experience rather than a controlled trial or peer-reviewed study, limiting generalizability. The summary is based on the podcast abstract and episode description only, as the full audio was not analyzed in detail. Sponsor mentions and personal product endorsements are present throughout the episode, which may introduce bias in supplement and device recommendations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: